Managed Care Information - Penlac® Nail Lacquer
FOR U.S. RESIDENTS ONLY
PenlacĀ® Nail Lacquer (ciclopirox) Topical Solution, 8%: Safe and on target
About Nail Fungus Treatment with Penlac® For People with Diabetes For Healthcare Professionals
Search













Managed Care Information

Managed care assistance when prescribing Penlac®

Managed Care Prior Authorization Requirements for onychomycosis:

  • Onychomycosis (tinea unguium; ICD-9 code 110.1)

Most managed care organizations require a positive diagnosis of onychomycosis, either through KOH test or positive culture. Refills may require additional authorization.

Managed care organizations may require one or more of the following conditions as a prerequisite to reimbursement of topical prescription therapy for onychomycosis:

  • Pain, decreased function or mobility, infection
  • Diabetes
  • Peripheral vascular disease
  • Multiple digits involved
  • Immunocompromised
  • Concern of liver toxicity with oral antifungal agents
  • Possible interactions with current medication

Because third-party reimbursement is affected by many factors, Dermik makes no representation or guarantee that you will be successful in obtaining insurance reimbursement. As reimbursement codes may change with time, please confirm code use with managed care organization.

ICD-9 codes associated with onychomycosis

Please refer to specific insurer guidelines for individual patient coverage.

Abnormality of gait781.2
Cellulitis of toe681.10
Difficulty walking719.77
Disease (nail, unspecified)703.9
Dystrophic nail703.8
Onychomycosis110.1
Pain (foot/limb)729.5
Paronychia of finger681.02
Paronychia of toe681.11
Peripheral vascular disease443.9
Tinea pedis110.4
Tinea unguium110.1

Penlac® is indicated in immunocompetent patients with mild to moderate onychomycosis without lunula involvement due to Trichophyton rubrum.
IMPORTANT SAFETY INFORMATION
Penlac®, part of a comprehensive management program, includes regular removal of the unattached, infected nail by a health care professional, especially for patients with diabetes. Clinical data regarding use of systemic antifungals and Penlac® is not available to support concomitant use. Penlac® is well-tolerated: treatment-related side effects were periungual erythema (5%) and nail disorders (2%).

Patients with insulin-dependent diabetes or those with diabetic neuropathy were not included in pivotal clinical trials with Penlac®.
For more information, please see Full Prescribing Information for Penlac®

Your privacy
Dermik Laboratories respects your interest in keeping your personal health information private. The information you provide below will be used only for the purpose of sending an email message to the recipient and will not be saved. For more information, see our Privacy Policy.

Your name:

Your email address:

Recipient's email address:






Processing...





Thank you!
Your email has been sent.